Abstract
BackgroundRomosozumab, a monoclonal antibody against sclerostin, is a newly licensed dual-acting osteoporosis (OP) treatment for patients at very high fracture risk. Most patients included in the pivotal trials (ARCH[1] and...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
